Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Genomic Revolution ETF (ARKG) vs Carnival Corp (CCL) Price & Performance

ARK Genomic Revolution ETFTrade
Carnival CorpTrade

Price performance (Past 24H)

Key statistics

ARK Genomic Revolution ETF vs Carnival Corp — how do they compare? ARK Genomic Revolution ETF trades at $44.6, while Carnival Corp trades at $27.67 (market cap $37.98B). The key difference: Carnival Corp pays a 1.62% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Carnival Corp nearer its low. Which is the better fit depends on your goals.

ARKGCCL
Sector
Sector/ThematicConsumer Cyclical
52-Week High
$44.55$33.99
52-Week Low
$24.02$23.89
Market Cap
$37.98B
Enterprise Value
$61.91B
Dividend Yield
1.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Genomic Revolution ETF

ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.

Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.

Carnival Corp

Carnival Corporation (CCL) trades at $27.77, showing minimal daily movement with a 0.07% gain. The stock demonstrates strong fundamental recovery with revenue growing from $12.2B in 2022 to $26.6B in 2025, while net income turned positive at $2.76B. Technical indicators show bearish momentum despite neutral oscillators, with key support at $27 and resistance at $28. Recent corporate developments include new voyage bookings through 2029 and continued dividend payments of $0.15 per share.

CCL presents a compelling recovery story with improving profitability and debt reduction, though near-term technical weakness and fuel cost risks persist. Analyst consensus remains bullish with a $35.18 price target representing 27% upside potential. The stock offers exposure to the rebounding cruise industry but faces sensitivity to economic conditions and operational execution challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG

About Carnival Corp

Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.

Read more on CCL